Search of prostatic tissue in 46,XX congenital adrenal hyperplasia

OBJETIVOS: Verificar a ocorrência de tecido prostático em pacientes portadoras da forma clássica de hiperplasia congênita das suprarrenais, com cariótipo 46,XX e analisar a sensibilidade e a especificidade do antígeno prostático específico (PSA) das pacientes com hiperplasia congênita das suprarrenais em relação à detecção de tecido prostático na ressonância magnética (RNM) de região pélvica. MÉTODOS: Foram estudadas 52 crianças e adolescentes, sendo 32 meninas portadoras da forma clássica de hiperplasia congênita das suprarrenais, 10 meninas e 10 meninos sem hiperplasia congênita das suprarrenais. A RNM da região pélvica e a coleta de PSA, diidrotestosterona e testosterona foram realizadas em todos os pacientes. Para analisar a capacidade de discriminação do antígeno prostático-específico, foi utilizada a curva ROC (receiver operating characteristic curve). RESULTADOS: Cinco das 32 pacientes portadoras de hiperplasia congênita das suprarrenais apresentaram tecido prostático na RNM de região pélvica. Para concentração de antígeno prostático-específico de 0,1 ng/mL, obteve-se sensibilidade de 100% e especificidade de 88,9% para a detecção de tecido prostático. CONCLUSÕES: A ocorrência de tecido prostático nas pacientes portadoras de hiperplasia congênita das suprarrenais estudadas foi de 15,6%. O antígeno prostático-específico mostrou ser valioso marcador de tecido prostático nestas pacientes.OBJECTIVES: To describe the presence of prostatic tissue in 46,XX patients with the classical form of congenital adrenal hyperplasia (CAH); to evaluate the sensitivity and specificity of prostatic specific antigen (PSA) measured in congenital adrenal hyperplasia patients with regard to the detection of prostatic tissue in pelvic MRI. METHODS: We studied 52 children and adolescents, 32 with the classical form of congenital adrenal hyperplasia, 10 boys and 10 girls without CAH. Pelvic MRI was performed in all patients to detect prostatic tissue. Prostate specific antigen, testosterone and dihydrotestosterone were measured in all patients. We used Receiver Operating Characteristic Curve for PSA discrimination capacity. RESULTS: Five girls with congenital adrenal hyperplasia showed image of prostatic tissue on pelvic MRI. Prostate specific antigen showed sensitivity and specificity of 100% and 88.9%, respectively, taking 0.1 ng/mL as the cutoff level. CONCLUSIONS: The incidence of prostatic tissue in 46,XX patients with the classical form of congenital adrenal hyperplasia was 15.6%. PSA demonstrated to be a good marker of prostatic tissue in these patients and should be used to screen patients to be submitted to image studies

A novel DAX1/NR0B1 mutation in a patient with adrenal hypoplasia congenita and hypogonadotropic hypogonadism

We report a case of adrenal hypoplasia congenita (AHC) and hypogonadotropic hypogonadism (HH) due to a novel DAX1 mutation. A 19-month-old boy with hyperpigmentation and failure to thrive came to our service for investigation. Three brothers of the patient had died due to adrenal failure, and a maternal cousin had adrenal insufficiency. Adrenoleukodystrophy was excluded. MRI showed normal pituitary and hypothalamus. Plasma hormone evaluation revealed high ACTH (up to 2,790 pg/mL), and low levels of androstenedione, DHEA-S, 11-deoxycortisol, and cortisol. At 14 years of age the patient was still prepubescent, his weight was 43.6 kg (SDS: -0.87) and his height was 161 cm (SDS: -0.36), with normal body proportions. In the GnRH test, basal and maximum values of LH and FSH were respectively 0.6/2.1 and < 1.0/< 1.0 U/L. Molecular investigation identified a novel mutation that consists of a deletion of codon 372 (AAC; asparagine) in exon 1 of DAX1. This mutation was not found in a study of 200 alleles from normal individuals. Prediction site analysis indicated that this alteration, located in the DAX1 ligand-binding domain, may damage DAX1 protein. We hypothesize that the novel (p.Asp372del) DAX1 mutation might be able to cause a disruption of DAX1 function, and is probably involved in the development of AHC and HH in this patient. Arq Bras Endocrinol Metab. 2012;56(8):496-50

Inhibin A generation after gonadotropin stimulus: a new method to detect ovarian tissue in true hermaphrodites

Introdução: O hermafroditismo verdadeiro, caracterizado pela demonstração histológica de tecido ovariano e testicular no mesmo indivíduo, responde por cerca de 5% dos casos de anomalia da diferenciação sexual. Como a variabilidade fenotípica é muito grande, desde mulheres com genitália externa normal até homens com genitália externa normal, passando por toda uma gama de apresentações intermediárias, torna-se impossível o diagnóstico baseado apenas em dados clínicos. A avaliação da presença de tecido testicular é bem estabelecida, mas não há teste para a demontração de tecido ovariano. A inibina A é produzida exclusivamente no ovário e é estimulada pelas gonadotrofinas. Objetivos: 1. Avaliar a efetividade do método de estimulação gonadal com a associação LH/FSH na demonstração de tecido ovariano; 2. Avaliar a eventual presença de tecido ovariano em pacientes com anomalias da diferenciação sexual através da dosagem sérica de Inibina A e de estradiol após estímulo gonadotrófico e; 3. Facilitar o diagnóstico de hermafroditismo verdadeiro antes da fase de exploração cirúrgica das gônadas. Métodos: Foram incluídos no estudo, dez pacientes com hiperplasia congênita de supra-renal, dez pacientes com criptorquidia unilateral isolada, treze pacientes com anomalia da diferenciação sexual sem etiologia definida e sete pacientes com hermafroditismo verdadeiro com diagnóstico histológico. Todos os pacientes foram submetidos a um teste de estímulo gonadotrófico, representado pela administração de gonadotrofina humana da menopausa (menotropina), que tem em sua composição LH e FSH, na dose de 150 UI de cada gonadotrofina, por via intramuscular, durante três dias subseqüentes. Dosagens de LH, FSH, estradiol, testosterora e inibina A foram realizadas antes (B), 24h após a primeira dose (A1) e 24 horas após a terceira dose (A2). Resultados: O LH não apresentou elevação significativa nos quatro grupos. O FSH elevou-se nos quatro grupos de forma progressiva e semelhante. O estradiol elevou-se significativamente nos grupos de pacientes com hiperplasia congênita das supra-renais (p=0,005) e de pacientes com hermafroditismo verdadeiro (p=0,031), enquanto a testosterona elevou-se nos grupos com criptorquidia isolada (p=0,027) e de pacientes com ambigüidade genital sem etiologia definida (p=0,028). A inibina A elevou-se significativamente nos grupos de pacientes com hiperplasia congênita das supra-renais (p=0,005) e com hermafroditismo verdadeiro (p=0,043). Conclusão: O teste de estímulo com LH e FSH mostrou-se útil para o diagnóstico da presença de tecido ovariano tanto em pacientes com hiperplasia congênita das supra-renais, como naqueles com hermafroditismo verdadeiro.Introduction: True hermaphrodism (TH) is characterized by the presence of ovarian and testicular tissue in the same patient comprises 5% of the intersex cases. A large spectrum of phenotypical variation is observed, ranging from normal female genitalia to normal male genitalia, covering a wide range of intermediary presentations, it becomes very difficult to make the diagnosis of TH on clinical basis. The detection of testicular tissue is well stablished but there is no available test to demonstrate the presence of ovarian tissue. Objectives: 1. To evaluate the effectiveness of the LH/FSH gonadal stimulation in demonstrating ovarian functiom 2. To evaluate the presence of ovarian tissue in intersex patients under gonadotropic stimulation and 3. To make the TH diagnosis before the surgical procedure. Patients and Methods: Ten patients with congenital adrenal hyperplasia (CAH), 10 with unilateral cryptorchidism, 13 intersex patients with no defined etiology, and seven TH patients have been included in the study. All the patients had a gonadotropic stimulation test with human menopausal gonadotropin (menotropin-hMG),150 IU, intramuscular, for three consecutive days. LH, FSH, estradiol, testosterone, and Inhibin A were measured before (0 time), 24h after the first gonadotropin dose, and 24h after the third gonadotropin dose. Results: LH did not show any significant increase in the four groups studied. FSH increased in the four groups in a similar way. Estradiol increased in CAH pacients (p=0.005) and in TH patients (p=0,031), while testosterone increased in patients whit unilateral cryptorchidism (p=0.027) as well as in the intersex patients without defined etiology. Inhibin A levels increased in CAH patients (p=0.005) and in the TH patients (p=0.043). Conclusion: The LH/FSH stimulation test demonstrated to be a useful method to diagnose the presence of ovarian tissue in CAH patients as well as in TH patients, becoming an important tool to diagnose TH even before the surgical procedure and histologic studies of the gonads

Laparoscopic sleeve gastrectomy in severely obese adolescents: effects on metabolic profile

ABSTRACT Objective: The objective was to conduct clinical and metabolic evaluations of obese adolescents before and after laparoscopic sleeve gastrectomy (LSG) (up to 24 months). Subjects and methods: This was designed as a retrospective, descriptive series of cases study, conducted in Instituto da Criança, São Paulo, Brazil. Analysis of clinical and laboratory data from 22 obese adolescents between 14 and 19 years old submitted to LSG between 2007 and 2014. Patients had BMI > 40 kg/m2 or BMI > 35 kg/m2 with comorbidities. Anthropometric, clinical and laboratory assessments were performed: before surgery, 6, 12, 18, and 24 months after surgery. We assessed weight loss and metabolic changes up to 24 months after LSG. Results: The mean preoperative weight and BMI were 128.5 kg (SD = 23.1) and 46.5 kg/m2 (SD = 74), respectively. There was an average weight loss of 34.5 kg in the first 12 months’ post LSG, corresponding to a 60% excess weight loss (EWL), as well as an average reduction in BMI of 12.3 kg/m2. However, after 24 months, the average EWL was 45%, corresponding to an average weight regain (WR) of 13.3 kg (15%) within two years. LSG improved dyslipidemia in 67.8% of patients, a significant remission of hepatic steatosis 47% and 37.7% systemic arterial hypertension; type 2 diabetes remission was complete. Conclusions: LSG proved to be a safe and effective procedure and seems to be the new hope for the obesity epidemic

Laparoscopic sleeve gastrectomy in severely obese adolescents: effects on metabolic profile

<div><p>ABSTRACT Objective: The objective was to conduct clinical and metabolic evaluations of obese adolescents before and after laparoscopic sleeve gastrectomy (LSG) (up to 24 months). Subjects and methods: This was designed as a retrospective, descriptive series of cases study, conducted in Instituto da Criança, São Paulo, Brazil. Analysis of clinical and laboratory data from 22 obese adolescents between 14 and 19 years old submitted to LSG between 2007 and 2014. Patients had BMI > 40 kg/m2 or BMI > 35 kg/m2 with comorbidities. Anthropometric, clinical and laboratory assessments were performed: before surgery, 6, 12, 18, and 24 months after surgery. We assessed weight loss and metabolic changes up to 24 months after LSG. Results: The mean preoperative weight and BMI were 128.5 kg (SD = 23.1) and 46.5 kg/m2 (SD = 74), respectively. There was an average weight loss of 34.5 kg in the first 12 months’ post LSG, corresponding to a 60% excess weight loss (EWL), as well as an average reduction in BMI of 12.3 kg/m2. However, after 24 months, the average EWL was 45%, corresponding to an average weight regain (WR) of 13.3 kg (15%) within two years. LSG improved dyslipidemia in 67.8% of patients, a significant remission of hepatic steatosis 47% and 37.7% systemic arterial hypertension; type 2 diabetes remission was complete. Conclusions: LSG proved to be a safe and effective procedure and seems to be the new hope for the obesity epidemic.</p></div

Diagnosis of 5α-reductase type 2 deficiency: Contribution of anti-Müllerian hormone evaluation

Aim: To evaluate anti-Müllerian hormone (AMH) levels in patients with clinical and molecular diagnosis of 5α-reductase 2 deficiency. Patients and methods: Data from 14 patients whose age ranged from 21 days to 29 years were analyzed according to age and pubertal stage. Sexual ambiguity was rated as Prader III in 11 patients. LH, FSH, testosterone (T), dihydrotestosterone (DHT) and AMH serum levels were measured in all but two patients, who had been previously submitted to gonadectomy; T and DHT were also measured in 20 age-matched controls. Results: Gonadotropin levels were normal in all but one patient who retained gonads (six of whom had reached puberty) and T/DHT ratio was elevated in all patients when compared to controls. All prepubertal patients had AMH levels < -1 SD for age, while most pubertal patients had AMH levels compatible with pubertal stage. Conclusions: Prepubertal patients with 5α-reductase 2 deficiency have AMH values in the lower part of the normal range. These data indicate that T does not need to be converted to DHT to inhibit AMH secretion by Sertoli cells. © Freund Publishing House Ltd., London